Teva Pharmaceutical Industries Limited (F:TEV) — Market Cap & Net Worth
Market Cap & Net Worth: Teva Pharmaceutical Industries Limited (TEV)
Teva Pharmaceutical Industries Limited (F:TEV) has a market capitalization of $34.58 Billion (€29.58 Billion) as of September 16, 2026. Listed on the F stock exchange, this Germany-based company holds position #794 globally and #170 in its home market, demonstrating a 9.58% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Teva Pharmaceutical Industries Limited's stock price €28.60 by its total outstanding shares 1164426972 (1.16 Billion). Also see Teva Pharmaceutical Industries Limited asset portfolio for a full breakdown of the balance sheet.
Teva Pharmaceutical Industries Limited Market Cap History: 2015 to 2026
Teva Pharmaceutical Industries Limited's market capitalization history from 2015 to 2026. Data shows change from $76.63 Billion to $38.93 Billion (-5.17% CAGR). Also see Teva Pharmaceutical Industries Limited cash flow conversion for how efficiently the company converts equity into cash flow.
Teva Pharmaceutical Industries Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Teva Pharmaceutical Industries Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Teva Pharmaceutical Industries Limited (TEV) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2.08x
Teva Pharmaceutical Industries Limited's market cap is 2.08 times its annual revenue
Latest Price to Earnings (P/E) Ratio
25.49x
Teva Pharmaceutical Industries Limited's market cap is 25.49 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $45.36 Billion | $21.90 Billion | $329.00 Million | 2.07x | 137.87x |
| 2017 | $21.37 Billion | $22.39 Billion | -$16.27 Billion | 0.95x | N/A |
| 2018 | $18.77 Billion | $18.85 Billion | -$2.15 Billion | 1.00x | N/A |
| 2019 | $11.98 Billion | $16.89 Billion | -$999.00 Million | 0.71x | N/A |
| 2020 | $10.74 Billion | $16.66 Billion | -$3.99 Billion | 0.64x | N/A |
| 2021 | $10.10 Billion | $15.88 Billion | $417.00 Million | 0.64x | 24.22x |
| 2022 | $11.65 Billion | $14.93 Billion | -$2.35 Billion | 0.78x | N/A |
| 2023 | $12.47 Billion | $15.85 Billion | -$559.00 Million | 0.79x | N/A |
| 2024 | $29.13 Billion | $16.54 Billion | -$1.64 Billion | 1.76x | N/A |
| 2025 | $35.94 Billion | $17.26 Billion | $1.41 Billion | 2.08x | 25.49x |
Competitor Companies of TEV by Market Capitalization
Companies near Teva Pharmaceutical Industries Limited in the global market cap rankings as of September 16, 2026. Review TEV tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Teva Pharmaceutical Industries Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #627 globally with a market cap of $44.32 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #639 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Haleon plc (NYSE:HLN): Ranked #662 globally with a market cap of $41.35 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #627 | GALDERMA GROUP AG | NYSE:GALDY | $44.32 Billion | $38.01 |
| #639 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €15.60 |
| #662 | Haleon plc | NYSE:HLN | $41.35 Billion | $9.39 |
Teva Pharmaceutical Industries Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Teva Pharmaceutical Industries Limited's market cap moved from $76.63 Billion to $ 38.93 Billion, with a yearly change of -5.17%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €38.93 Billion | +8.33% |
| 2025 | €35.94 Billion | +23.36% |
| 2024 | €29.13 Billion | +133.62% |
| 2023 | €12.47 Billion | +7.01% |
| 2022 | €11.65 Billion | +15.36% |
| 2021 | €10.10 Billion | -5.96% |
| 2020 | €10.74 Billion | -10.34% |
| 2019 | €11.98 Billion | -36.19% |
| 2018 | €18.77 Billion | -12.17% |
| 2017 | €21.37 Billion | -52.88% |
| 2016 | €45.36 Billion | -40.81% |
| 2015 | €76.63 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 15th, 2026 the market cap of Teva Pharmaceutical Industries Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $34.58 Billion USD |
| MoneyControl | $34.58 Billion USD |
| MarketWatch | $34.58 Billion USD |
| marketcap.company | $34.58 Billion USD |
| Reuters | $34.58 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-po… Read more